Skip to content
Screener

ImmunityBio, Inc. IBRX Total Liabilities & Equity

Total Liabilities & Equity at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
$87.63B-7.4%
Johnson & Johnson logo
Johnson & JohnsonJNJ
$201.06B+4.0%
Merck & Co. logo
Merck & Co.MRK
$129.8B+10.4%
Gilead Sciences logo
Gilead SciencesGILD
$49.36B-11.4%
Nektar Therapeutics logo
Nektar TherapeuticsNKTR
$763.27M+198%
Aura Biosciences, Inc. logo
Aura Biosciences, Inc.AURA
$137.68M-11.4%

Other financials

Income statement

See full
Revenue$44.2M+168%
Gross profit$44.0M+167%
Operating income-$69.8M-8.3%
Net income-$632.8M-388%
EPS (diluted)-$0.62-313%

Balance sheet

See full
Cash & equivalents$205.2M+238%
Total debt$445.4M+32.2%
Total equity-$870.0M-47.1%
Total assets$646.6M+113%

Cash flow

See full
Operating cash flow-$75.4M+12.3%
CapEx$1.8M+58.4%
Free cash flow-$77.1M+11.4%

Valuation

See full
Market cap$7.76B+245%
Enterprise value$8B+230%
P/S55×+15.3×

Profitability

See full
Gross margin99.3%-0.5pp
Operating margin-185.4%-83.3pp
Net margin-606.2%-212pp
FCF margin-212%-95.8pp

Returns & leverage

See full
Return on equity-119.3%
Debt / equity0.1×
Current ratio6.7×+4.4×

Where this comes from

Reported directly by ImmunityBio, Inc. in its filing.

Tagged under the XBRL concept us-gaap:LiabilitiesAndStockholdersEquity.

The source filing: ImmunityBio, Inc.’s 10-Q, filed May 7, 2026.

Filed
May 7, 2026, 7:37 AM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001326110-26-000059
Line itemMarch 31, 2026December 31, 2025
Common Stock, $0.0001 par value; 1,650,000,000 shares authorized as of March 31, 2026 and December 31, 2025; 1,047,341,146 and 1,011,800,008 shares issued and outstanding as of March 31, 2026 and December 31, 2025, respectively; excluding treasury stock, 163,800 shares outstanding as of March 31, 2026 and December 31, 2025$104$101
Additional paid-in capital3,461,8653,197,120
Accumulated deficit(4,359,428)(3,726,646)
Accumulated other comprehensive income27,45328,956
Total ImmunityBio stockholders’ deficit(870,006)(500,469)
Noncontrolling interests880895
Total stockholders’ deficit(869,126)(499,574)
Total liabilities and stockholders’ deficit$646,637$501,898

ITEM 1. FINANCIAL STATEMENTS.

FAQ

What is ImmunityBio, Inc.'s total liabilities & equity?
ImmunityBio, Inc. (IBRX) reported total liabilities & equity of $646.64M in Q1 2026.
How has ImmunityBio, Inc.'s total liabilities & equity changed year-over-year?
ImmunityBio, Inc.'s total liabilities & equity increased by 112.9% year-over-year, from $303.76M to $646.64M.
What is the long-term trend for ImmunityBio, Inc.'s total liabilities & equity?
Over 5 years (2020 to 2025), ImmunityBio, Inc.'s total liabilities & equity has grown at a 17.8% compound annual growth rate (CAGR), from $221.38M to $501.9M.
What does total liabilities & equity mean?
Total assets = total liabilities + total equity. This must always balance — a fundamental accounting identity.

Ask your AI about ImmunityBio, Inc.'s total liabilities & equity.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude